advanced hormone receptor-positive, HER2-negative breast cancer
GPTKB entity
Statements (26)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
breast cancer subtype
|
| gptkbp:guidanceSystem |
gptkb:NCCN_Guidelines
gptkb:ESMO_Guidelines |
| gptkbp:hasBiomarker |
HER2
estrogen receptor progesterone receptor |
| gptkbp:hasCommonMutations |
gptkb:PIK3CA
gptkb:BRCA1 gptkb:BRCA2 gptkb:ESR1 |
| gptkbp:hasHER2Status |
negative
|
| gptkbp:hasHormoneReceptorStatus |
positive
|
| gptkbp:hasTargetedTherapy |
gptkb:alpelisib
gptkb:palbociclib gptkb:ribociclib gptkb:fulvestrant gptkb:abemaciclib |
| https://www.w3.org/2000/01/rdf-schema#label |
advanced hormone receptor-positive, HER2-negative breast cancer
|
| gptkbp:prevalence |
most common subtype of metastatic breast cancer
|
| gptkbp:prognosis |
variable
|
| gptkbp:stageName |
advanced
|
| gptkbp:treatment |
chemotherapy
endocrine therapy CDK4/6 inhibitors |
| gptkbp:bfsParent |
gptkb:Afinitor
|
| gptkbp:bfsLayer |
5
|